Neurocrine Biosciences Announces Publication Of New Peer-Reviewed Research In The Journal Of Clinical Psychiatry Characterizing Patient-Reported Improvement With INGREZZA Capsules Across KINECT Clinical Program

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

NBIX

0.00
  • Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical program
  • Publication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™)

SAN DIEGO, April 29, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry demonstrating how the Tardive Dyskinesia Impact Scale helps characterize patient-reported burden in tardive dyskinesia and has been used in clinical studies to assess meaningful improvement over the course of treatment with INGREZZA® (valbenazine) capsules.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.